Merck & Co., Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
Merck & Co., Inc. (MRK) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of $12.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2024-02-26
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-06-30 was $3.00M, a 40.00% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-03-31 was $4.00M.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-12-31 was $1.00M, a 75.00% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-09-30 was $5.00M, a 25.00% increase year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2023 was $12.00M, a 71.43% increase from fiscal 2022.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was $7.00M, a 46.15% decline from fiscal 2021.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2021 was $13.00M, a 225.00% increase from fiscal 2020.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2020 was $4.00M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | $12.00M 10-K · filed 2024-02-26 | |||
| 2023-06-30 | $3.00M 10-Q · filed 2023-08-07 | $7.00M 10-Q · filed 2023-08-07 | $8.00M derived: sum of 3 quarters · filed 2024-02-26 | $13.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-03-31 | $4.00M 10-Q · filed 2023-05-05 | $5.00M derived: sum of 2 quarters · filed 2024-02-26 | $10.00M derived: sum of 3 quarters · filed 2024-02-26 | $15.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $6.00M derived: sum of 2 quarters · filed 2024-02-26 | $11.00M derived: sum of 3 quarters · filed 2024-02-26 | $7.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-03 | $10.00M derived: sum of 2 quarters · filed 2023-08-07 | $6.00M 10-Q · filed 2022-11-03 | $11.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $5.00M 10-Q · filed 2023-08-07 | $2.00M 10-Q · filed 2023-08-07 | $6.00M derived: sum of 3 quarters · filed 2024-02-26 | $10.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$3.00M 10-Q · filed 2023-05-05 | $1.00M derived: sum of 2 quarters · filed 2024-02-26 | $5.00M derived: sum of 3 quarters · filed 2024-02-26 | $6.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $8.00M derived: sum of 2 quarters · filed 2024-02-26 | $9.00M derived: sum of 3 quarters · filed 2024-02-26 | $13.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $4.00M 10-Q · filed 2022-11-03 | $5.00M derived: sum of 2 quarters · filed 2022-11-03 | $9.00M 10-Q · filed 2022-11-03 | $12.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-05 | $5.00M 10-Q · filed 2022-08-05 | $8.00M derived: sum of 3 quarters · filed 2023-02-24 | $10.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $4.00M 10-Q · filed 2022-05-05 | $7.00M derived: sum of 2 quarters · filed 2023-02-24 | $9.00M derived: sum of 3 quarters · filed 2023-02-24 | $13.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $5.00M derived: sum of 2 quarters · filed 2023-02-24 | $9.00M derived: sum of 3 quarters · filed 2023-02-24 | $4.00M 10-K · filed 2023-02-24 |
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-05 | $6.00M derived: sum of 2 quarters · filed 2021-11-05 | $1.00M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $4.00M 10-Q · filed 2021-08-09 | -$1.00M 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | -$84.00M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |